Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Safety of RVL-1201 in the Treatment of Acquired Blepharoptosis (Study RVL-1201-203)

NCT03536949 is registered in ClinicalTrials.gov with RVL Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03536949
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03536949 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Safety of RVL-1201 in the Treatment of Acquired Blepharoptosis (Study RVL-1201-203)
Lead sponsor
RVL Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
June 20, 2018
Completion date
March 27, 2019
Enrollment
234 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

blepharoptosis